您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > UC2288
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
UC2288
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
UC2288图片
规格:98%
分子量:481.82
包装与价格:
包装价格(元)
50mg电议
100mg电议
250mg电议

产品介绍
UC2288是一种新型的、具有细胞通透性和口服活性的p21衰减试剂(对p21具有相对选择性活性),基于索拉非尼的结构合成。UC2288在不依赖p53的情况下下调p21mRNA的表达,降低p21蛋白水平,对p21蛋白的稳定性影响很小。UC2288对VEGFR2和Raf激酶没有抑制作用,即使在10μM。
货号:ajcx29758
CAS:1394011-91-6
分子式:C20H18ClF6N3O2
分子量:481.82
溶解度:N/A
纯度:98%
存储:Store at -20°C
库存:现货

Background:

UC2288 is a novel, cell-permeable, and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib . UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels with minimal effect on p21 protein stability. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].

UC2288 (0-10 μM; 24 hours) decreases p21 protein level, but has no effects on other proteins[1].UC2288 (0-10 μM; 24 hours) decreases p21 mRNA expression transcriptionally or post-transcriptionally but independently of p53[1]. Western Blot Analysis[1] Cell Line: HK2 (normal kidney), 786-O (RCC), Caki-1 (RCC), ACHN (RCC) and HEY (ovarian cancer) cells

UC2888 (oral gavage; 15 mg/kg; 3 times a week; 4 weeks) co-treatment with imetelstat significantly suppresses tumor growth and does not effect mice weight[2].UC2288 (intraperitoneal injection; 10 mg/kg; 4 times in 7 days) attenuates MPTP-induced behavioral impairment, prevents activation of MAPK pathway in the MPTP-treated mice brain. MPTP treatment raises TNF-α, IL-6 and IL-1β levels in MPTP treated mice brain, but UC2288 signicantly decreases MPTP-induced TNF-α, IL-6 levels, but IL-1β is not decreased in brain[3]. Animal Model: Eight-week old, athymic nude (NCr nu/nu) mice injected subcutaneously with HCT116 and ACHN cancer cells(2.5x106)[2]

[1]. Hiromi I Wettersten, et al. A Novel p21 Attenuator Which Is Structurally Related to Sorafenib. Cancer Biol Ther. 2013 Mar;14(3):278-85. [2]. Romi Gupta, et al. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3062-71. [3]. Jun Hyung Im, et al. p21 inhibitor UC2288 ameliorates MPTP induced Parkinson's disease progression through inhibition of oxidative stress and neuroinammation. Translational Medicine.Neurobiology of Disease